TITLE

NeoPharm: more promising survival data for cintredekin besudotox

PUB. DATE
June 2006
SOURCE
PharmaWatch: Cancer;Jun2006, Vol. 5 Issue 6, p11
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article reports on NeoPharm's release of update phase I/II data for cintredekin besudotox that shows increased survival in glioblastoma multiforme patients. The drug is a chimeric interleukin-13 conjugated to a genetically engineered Pseudomonas exotoxin. The phase III trial was initiated in March 2004 by the company.
ACCESSION #
21261119

 

Related Articles

  • NeoPharm: more promising survival data for cintredekin besudotox.  // PharmaWatch: Biotechnology;Jun2006, Vol. 5 Issue 6, p5 

    The article reports on NeoPharm Inc.'s release of the results of phase I/II clinical trial of hts cintredekin besudotox. The updated data showed that the overall median survival of the 45 patients with glioblastoma multiforme (GBM) was 44 weeks. Long-term follow-up demonstrated 22 patients with...

  • NeoPharm: more promising survival data for cintredekin besudotox.  // PharmaWatch: Monthly Review;Jun2006, Vol. 5 Issue 6, p7 

    The article comments on the results of the phase I/II trial on the survival, drug safety and quality of life for glioblastoma multiforme (GM) patients receiving NeoPharm's cintredekin besudotox (CB). The data showed that the overall median survival of the patients with GM was 44 weeks. CB or IL...

  • FDA Wants Another Phase III For NeoPharm's GBM Drug. Morrison, Trista // BioWorld Today;3/30/2007, Vol. 18 Issue 62, p2 

    The author reports on the demand by the U.S. Food and Drug Administration (FDA) Office of Oncology for another phase III trial of cintredekin besudotox, before granting approval for its use in the treatment of recurrent glioblastoma multiforme. The drug failed to meet its primary endpoint in a...

  • NeoPharm reaches agreement with FDA on phase III "Precise" trial.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p20 

    Reports that NeoPharm Inc. reached an agreement with the Food and Drug Administration regarding its Precise trial designed to be a study of the company's experimental tumor-targeting, anticancer drug IL13-PE38QQR, that is being investigated as a treatment for first recurrence of glioblastoma...

  • ATTACKING BRAIN TUMORS HEAD-ON. Karpa, Kelly Dowhower // Drug Topics;9/18/2006, Vol. 150 Issue 18, special section p9 

    The article explains that 34 drugs are in clinical trials for the treatment of glioblastoma multiforme and brain tumors, which means pharmacists will be playing an expanded role in the treatment of these diseases. A monoclonal antibody called bevacizumab inhibits the activity of vascular...

  • Interleukin-13 Displaying Retargeted Oncolytic Measles Virus Strains Have Significant Activity Against Gliomas With Improved Specificity. Allen, Cory; Paraskevakou, Georgia; Iankov, Ianko; Giannini, Caterina; Schroeder, Mark; Sarkaria, Jann; Puri, Raj K; Russell, Stephen J; Galanis, Evanthia // Molecular Therapy;Sep2008, Vol. 16 Issue 9, p1556 

    The majority of glioblastoma multiforme (GBM) tumors (80%) overexpress interleukin-13 receptor α2 (IL-13Rα2), but there is no expression of IL-13Rα2 in normal brain. Vaccine strains of measles virus have significant antitumor activity against gliomas. We tested the hypothesis that...

  • ASCO 2011 Roundup.  // BioWorld Today;6/7/2011, Vol. 22 Issue 109, p3 

    The article focuses on a report by Agenus Inc. during the 2011 annual meeting of the American Society of Clinical Oncology (ASCO), that its Phase II trial revealed that its Series G-200 vaccine could give patients with glioblastoma multiforme a median overall survival of 11 months.

  • EOPHARM BEGINS TRIAL OF IL13-PE38 FOR MALIGNANT GLIOMA.  // Worldwide Biotech;Oct2002, Vol. 14 Issue 10, p4 

    Highlights progress on the clinical development program of NeoPharm Inc. for IL13-PE38, a novel tumor-targeted agent.

  • Taking on a Monster. Egan, Mary Ellen // Forbes Global;11/15/2004, Vol. 7 Issue 20, p64 

    Offers a look on two prospective drugs for brain cancer, IL-13 and Transmid, that are giving patients a new lease on life as of 20014. Background on the case of David Herbert, a former pilot diagnosed with glioblastoma multiforme; Makers of IL-13 and Transmid; Number of U.S. citizens diagnosed...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics